ACRIVON THERAPEUTICS INC (ACRV) Stock Income Statement
USA - NASDAQ:ACRV - US0048901096 - Common Stock
2.24 USD
+0.17 (+8.21%)
2.22 USD
-0.02 (-0.89%)
| TTM (2025-6-30) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | |||
| Gross Premiums Earned | null | null | null | null | null | |||
| Loss Claims | null | null | null | null | null | |||
| Deferred Policy Acquisition Expense | null | null | null | null | null | |||
| Net Interest Income | null | null | null | null | null | |||
| Non Interest Income | null | null | null | null | null | |||
| Loan Loss Provision | null | null | null | null | null | |||
| Net Interest Income after Provision | null | null | null | null | null | |||
| Non Interest Expense | null | null | null | null | null | |||
| Minority Interest Expense | null | null | null | null | null | |||
| Cost Of Goods | null | null | null | null | null | |||
| Gross Profit | null | null | null | null | null | |||
| Operating Expenses | 94.41M | 89.20M | 67.10M | 32.66M | 16.18M | |||
| Research and Development | 69.09M | 63.99M | 46.02M | 23.95M | 13.72M | |||
| Selling, General, and Administrative Expenses | 25.32M | 25.21M | 21.08M | 8.71M | 2.47M | |||
| Operating Income | -94.41M | -89.20M | -67.10M | -32.66M | -16.18M | |||
| Interest Income/Expense | 8.79M | 9.20M | null | null | 0 | |||
| Other Income/Expense | -340.00K | -558.00K | 6.71M | 1.49M | -160.00K | |||
| Non Recurring Items | null | null | null | null | 100.00K | |||
| Income Before Taxes | -85.96M | -80.56M | -60.39M | -31.17M | -16.24M | |||
| Income Tax | null | null | null | null | null | |||
| Net Income | -85.96M | -80.56M | -60.39M | -31.17M | -16.24M | |||
| EBITDA | -93.20M | -88.19M | -66.57M | -32.30M | -16.14M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -2.2448 | -2.3839 | -2.7352 | -1.42 | -0.78 | |||
| Non GAAP EPS | -2.25 | -2.44 | -2.73 | null | null | |||
| Statistics | ||||||||
All data in USD